Revolutionizing the World of Therapeutic ADC Development




The Company

Quadira Biosciences combines two outstanding cutting-edge technology platforms to complete the development and preclinical studies of ten new Antibody Drug Conjugates (ADCs) within 4 months each. This dramatically extend the previously rather limited commercial lifecycle of antibody drugs. Collectively, the planned ADC portfolio has a market value of $25 billion. The first new anti-HER-2 ADC has already been completed and documented in the last months and is currently under preparation for licensing.

Technology Platforms 

The unique technology setup of Quadira Biosciences was created by a joint venture between anfass Life Technologies and Xlife. It combines two outstanding cutting-edge technologies to complete designing, screening and defining of highly effective new therapeutic antibody drug conjugates including preclinical studies in the shortest time possible using a novel kind of click chemistry and a unique physiological 3D approach.

OUR FIRST ADC PRODUCT QBK249-G is a HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid breast tumors. Preclinical evaluation shows 8-fold higher antitumor efficacy compared to the currently marketed ADC at a comparable toxicity at a 10-fold lower concentration, promising massively improved biotolerability. QBK249-G has also proven to kill effectively dormant tumor cells.

Quadira Biosciences' innovative and unique technology platform has thus impressively demonstrated its exceptional speed and efficiency. QBK249-G is already in the patenting process and licensing documents are under preparation. The next ADC in the product pipeline has also been developed and is now entering the preclinical evaluation phase.



Strategic Partners